Targeting toll-like receptors on T cells as a therapeutic strategy against tumors

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Innate and adaptive immunity are vital for anti-tumor responses.
• T cell-based therapies, including immune checkpoint inhibitors and CAR T cells, show promise in hematologic malignancies.
• Toll-like receptors (TLRs), typically innate immune cell receptors, also play a role in T cell-mediated anti-tumor immunity.

Purpose of the Study:

• To summarize advances in understanding TLRs' role in activating T cell anti-tumor immunity.
• To discuss the potential of TLR agonists in combination cancer therapies.

Main Methods:

• Review of current literature on TLR signaling pathways in T cells.
• Analysis of studies demonstrating TLRs' intrinsic contribution to anti-tumor responses.
• Exploration of therapeutic strategies involving TLR agonists.

Main Results:

• Various TLRs and their downstream pathways can activate T cell anti-tumor immunity.
• TLRs intrinsically contribute to T cell-mediated anti-tumor responses.
• TLR agonists have potential to enhance existing cancer immunotherapies.

Conclusions:

• TLRs are important intrinsic regulators of T cell anti-tumor immunity.
• TLR agonists represent a promising strategy to augment the efficacy of T cell-based cancer therapies.